I'm A Patient
I'm A Provider
Overview
Dry AMD treatment devices vary significantly, from the strength and design of their supporting evidence to their regulatory approval status and scope. Clinicians evaluating devices should assess a few factors independently rather than relying on marketing materials or word of mouth. For patients, understanding these dimensions can help set realistic expectations and ask better questions at a consultation.1
When comparing devices, consider the design and quality of the published clinical evidence, regulatory authorization, and the trial data behind the device.
Considerations When Evaluating Devices
1. Regulatory Approval
Any device used in a clinical setting for the treatment of dry AMD should hold regulatory approval from the relevant authority in the country of use. Regulatory approval is a starting point, but it is not a quality ranking. Two devices may both hold Health Canada authorization while differing substantially in the strength of the underlying evidence.
Clinicians should verify that the approval covers the specific indication being claimed. A device approved for a related but distinct condition is not the same as one authorized specifically for dry AMD, and the evidence base supporting that distinction matters.
2. Clinical Trial Design
The good starting point for choosing a device to improve visual function in dry AMD is a published, peer-reviewed randomized controlled trial with a sham control. A sham control is important in device trials because patients who believe they are being treated tend to report improvements regardless of whether the active intervention is working, a phenomenon sometimes called the placebo or expectation effect. A well-designed sham mimics the treatment experience in every observable respect except the active component.2
Beyond the sham control, consider quality indicators in a dry AMD device trial. This could include pre-specified primary endpoints rather than endpoints chosen after data collection, validated outcome measures such as ETDRS visual acuity and contrast sensitivity testing, a sample size calculated to detect a clinically meaningful difference, and independent statistical analysis with transparent reporting of all outcomes including adverse events.
Clinicians should read the published trial itself, not a manufacturer-provided summary. Summaries may selectively present findings or omit results from subgroups that did not respond as strongly.
3. Approved Indication
The authorized indication describes the intended use, including the patient population and clinical purpose for which the device is licensed. For dry AMD devices in this category, the authorized indication is improvement of visual function, specifically, measures like visual acuity and contrast sensitivity, not prevention of AMD progression, restoration of lost vision or any claim about disease course.1
This distinction has practical consequences. A clinician or patient expecting a device to slow or halt progression is expecting something outside its approved indication and outside the evidence base supporting it. Managing that expectation clearly, before treatment begins, is part of responsible clinical practice.2
It also means devices authorized to improve visual function and interventions aimed at reducing progression risk, such as AREDS2 supplementation, are not competing alternatives. They address different aspects of AMD management and can be used together in a comprehensive care plan.
4. Patient Eligibility
The population enrolled in a device’s clinical trial defines the population for whom the evidence is most directly applicable. A clinician recommending a device to a patient whose characteristics differ meaningfully from the trial population is extrapolating from the evidence rather than applying it directly. That is not necessarily wrong, but it requires transparency with the patient about what is and is not known.2
For MacuMira, the published trial enrolled patients with dry AMD and best-corrected visual acuity between 20/50 and 20/200. Patients whose baseline vision falls outside the population studied in the trial may respond differently, so clinicians should discuss how closely an individual patient’s situation matches the available evidence. This does not mean such patients cannot benefit, but the gains are likely to be smaller, and the conversation about expected outcomes should reflect that.4
5. Treatment Protocol
Devices with a published, standardized treatment protocol may offer more predictable outcomes and clearer expectations for patients and clinicians alike. A defined protocol specifies session frequency, session duration, electrode placement, stimulation parameters and the maintenance schedule required to sustain benefit over time.4
For MacuMira, treatment follows a defined protocol, with follow-up treatments typically recommended after the initial treatment period. The treating eye care provider can determine the appropriate schedule based on the patient’s condition and response.
6. Safety Record
Post-market safety data provides a different kind of evidence from a clinical trial. Trials are conducted under controlled conditions with selected patients, but real-world use involves a broader population, more variable clinical environments and longer follow-up. A strong post-market safety record across a substantial number of treatments, clinics and countries adds meaningful confidence beyond what a trial can provide alone.4
MacuMira’s published real-world data covers more than 21,000 treatments delivered across hundreds of clinics in three countries. The trial and post-market use have reported no device-related serious adverse events.
Clinicians evaluating a device should ask the manufacturer directly for post-market safety data, including any adverse event reports submitted to regulatory authorities. This information may not be prominently featured in promotional materials but is available through formal channels.
How Device-Based Therapy Fits Into a Broader AMD Management Plan
No single device or intervention addresses every aspect of dry AMD management. Authorized device-based therapy to improve visual function is most useful when integrated into a care plan that also includes regular monitoring with retinal imaging, AREDS2 supplementation for eligible patients, and lifestyle modifications that reduce progression risk. These elements address different aspects of the disease and are not mutually exclusive.1
Patients who are candidates for device-based therapy should continue their monitoring schedule. If a patient’s condition changes, for example, if there are signs of conversion from dry to wet AMD, the clinical team needs to detect that change and respond appropriately. Device-based therapy does not replace the surveillance function of regular eye examinations.
For patients with significant functional vision loss that has already occurred, low vision rehabilitation may also be appropriate alongside or instead of device-based therapy, depending on where they are in the disease course.
Questions to Ask When Comparing Devices
- Does this device hold regulatory authorization in Canada specifically for dry AMD?
- Has the device been studied in a published, peer-reviewed randomized sham-controlled trial? What were the primary endpoints and results?2
- What patient population was studied, and does this patient’s baseline acuity and AMD stage fall within that range?
- What is the device intended to do and what is it not intended to do?
- What is the defined treatment protocol, including initial course and ongoing maintenance schedule?4
- How many real-world treatments have been delivered and what is the post-market adverse event record?4
- Is the device contraindicated for any condition this patient has, including wet AMD, implanted electronic devices or other relevant factors?
Conclusion
Comparing dry AMD treatment devices for clinic use requires independently evaluating regulatory approval, clinical trial quality, authorized indication, patient eligibility criteria, treatment protocol, and real-world safety data. Regulatory approval is a minimum threshold, not a quality guarantee. A randomized, sham-controlled trial can provide strong evidence about whether a device improves the outcomes it was designed to measure. MacuMira is an authorized device indicated to improve visual function in patients with dry AMD.
Disclaimer
This article is for educational and informational purposes only. It does not constitute a clinical endorsement of any specific device or approach and does not replace the professional judgment of a licensed eye care provider. Clinicians should apply their own assessment of the evidence when making treatment decisions. Patients should consult a qualified eye care professional before beginning any treatment for dry AMD.
Glossary
Health Canada Medical Device Licence: Regulatory authorization confirming that a medical device meets Canadian standards for safety and efficacy for its approved indication.
Sham-controlled trial: A clinical trial design in which the control group receives a treatment mimicking the active intervention in all observable respects except the active component. Critical for eliminating expectation effects in device trials.
ETDRS scale: The Early Treatment Diabetic Retinopathy Study visual acuity scale, scored letter by letter. The standard outcome measure in AMD clinical trials.
Contrast sensitivity: The ability to distinguish objects from their background at varying contrast levels. Assessed independently of high-contrast visual acuity in dry AMD trials.
Ceiling effect: In clinical measurement, the phenomenon where patients near the upper limit of a scale have limited room to show further improvement, reducing measurable effect size.
Approved indication: The specific clinical purpose for which a regulatory body has accepted evidence of a device’s safety and efficacy. Use outside the approved indication is off-label.
MacuMira: An approved medical device indicated to improve visual function in patients with dry AMD, delivered via low-level electrical stimulation in a clinical setting. For use under the supervision of an eye care professional. Not indicated for wet AMD.
AREDS2 formula: A nutritional supplement combination shown to reduce progression risk to advanced AMD in eligible patients. Addresses progression risk rather than visual function improvement, complementary to, not competitive with, device-based therapy.
Post-market surveillance: Ongoing monitoring of a medical device’s safety and performance after regulatory approval, through adverse event reporting and real-world outcome tracking.
Dry AMD: A progressive retinal condition affecting the macula. The most common form of AMD. Distinct from wet AMD in pathophysiology and treatment approach.
References
1. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.
2. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.
3. Medical Device Licences. Health Canada. Date not listed. Accessed June 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/licences.html.
4. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.
5. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. AREDS2 Research Group. JAMA. Published May 15, 2013. Accessed June 2026. https://jamanetwork.com/journals/jama/fullarticle/1684847
